Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Trauma, Nervous System

ClinicalTrials.gov lists 5,496 trials for Trauma, Nervous System or a narrower condition beneath it. VA Office of Research and Development has the most among industry and government lead sponsors, with 160.

MeSH D020196 Nervous System Diseases C10 C26
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 246 Phase 1/2 Phase 1/2 122 Phase 2 Phase 2 321 Phase 2/3 Phase 2/3 73 Phase 3 Phase 3 162 Phase 4 Phase 4 164 Not applicable Not applicable 2,968 Observational Observational 1,434 Phase 1 Phase 1 246 Phase 1/2 Phase 1/2 122 Phase 2 Phase 2 321 Phase 2/3 Phase 2/3 73 Phase 3 Phase 3 162 Phase 4 Phase 4 164 Not applicable Not applicable 2,968 Observational Observational 1,434

Trials per phase (log scale)

1 more section with rows

78 of the 5,496 trials are tagged with Trauma, Nervous System itself; the rest are tagged with a narrower condition beneath it.

Get the Trauma, Nervous System report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Trauma, Nervous System trials start? (35)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 26 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 407

1991: 4 trials (Observational 1, Not applicable 1, Phase 3 2) 1992: 2 trials (Observational 2) 1993: 2 trials (Not applicable 1, Phase 3 1) 1995: 1 trials (Phase 2 1) 1996: 6 trials (Observational 1, Not applicable 3, Phase 4 1, Phase 2 1) 1997: 2 trials (Observational 1, Phase 2 1) 1998: 11 trials (Observational 6, Phase 3 1, Phase 2 4) 1999: 6 trials (Observational 1, Not applicable 2, Phase 2 2, Phase 1 1) 2000: 9 trials (Observational 2, Not applicable 3, Phase 3 1, Phase 2/3 1, Phase 2 2) 2001: 6 trials (Observational 2, Not applicable 2, Phase 3 1, Phase 1 1) 2002: 32 trials (Observational 2, Not applicable 8, Phase 4 7, Phase 3 6, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 5) 2003: 47 trials (Observational 9, Not applicable 14, Phase 4 5, Phase 3 3, Phase 2/3 6, Phase 2 7, Phase 1 3) 2004: 43 trials (Observational 12, Not applicable 15, Phase 4 2, Phase 3 4, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 4) 2005: 56 trials (Observational 16, Not applicable 17, Phase 4 6, Phase 3 4, Phase 2 5, Phase 1/2 5, Phase 1 3) 2006: 53 trials (Observational 13, Not applicable 16, Phase 4 5, Phase 3 4, Phase 2/3 4, Phase 2 5, Phase 1/2 1, Phase 1 5) 2007: 93 trials (Observational 39, Not applicable 21, Phase 4 8, Phase 3 5, Phase 2/3 3, Phase 2 9, Phase 1/2 2, Phase 1 6) 2008: 111 trials (Other 1, Observational 31, Not applicable 41, Phase 4 5, Phase 3 6, Phase 2/3 4, Phase 2 10, Phase 1/2 7, Phase 1 6) 2009: 106 trials (Observational 29, Not applicable 39, Phase 4 7, Phase 3 5, Phase 2/3 1, Phase 2 13, Phase 1/2 7, Phase 1 5) 2010: 131 trials (Observational 43, Not applicable 39, Phase 4 4, Phase 3 10, Phase 2/3 4, Phase 2 18, Phase 1/2 4, Phase 1 9) 2011: 168 trials (Observational 53, Not applicable 57, Phase 4 10, Phase 3 8, Phase 2/3 2, Phase 2 13, Phase 1/2 11, Phase 1 14) 2012: 160 trials (Observational 49, Not applicable 62, Phase 4 11, Phase 3 6, Phase 2/3 2, Phase 2 12, Phase 1/2 6, Phase 1 12) 2013: 200 trials (Observational 43, Not applicable 104, Phase 4 12, Phase 3 5, Phase 2/3 3, Phase 2 19, Phase 1/2 4, Phase 1 10) 2014: 222 trials (Observational 44, Not applicable 124, Phase 4 6, Phase 3 8, Phase 2/3 3, Phase 2 21, Phase 1/2 8, Phase 1 8) 2015: 248 trials (Observational 74, Not applicable 137, Phase 4 6, Phase 3 3, Phase 2/3 4, Phase 2 10, Phase 1/2 6, Phase 1 8) 2016: 271 trials (Observational 71, Not applicable 149, Phase 4 6, Phase 3 8, Phase 2/3 3, Phase 2 16, Phase 1/2 11, Phase 1 7) 2017: 292 trials (Observational 73, Not applicable 174, Phase 4 7, Phase 3 5, Phase 2/3 3, Phase 2 14, Phase 1/2 4, Phase 1 12) 2018: 312 trials (Observational 84, Not applicable 187, Phase 4 5, Phase 3 10, Phase 2/3 1, Phase 2 12, Phase 1/2 3, Phase 1 10) 2019: 335 trials (Observational 79, Not applicable 204, Phase 4 6, Phase 3 6, Phase 2/3 3, Phase 2 25, Phase 1/2 5, Phase 1 7) 2020: 293 trials (Observational 81, Not applicable 158, Phase 4 9, Phase 3 7, Phase 2/3 2, Phase 2 17, Phase 1/2 3, Phase 1 16) 2021: 407 trials (Observational 110, Not applicable 250, Phase 4 6, Phase 3 7, Phase 2/3 4, Phase 2 10, Phase 1/2 8, Phase 1 12) 2022: 330 trials (Observational 84, Not applicable 212, Phase 4 1, Phase 3 5, Phase 2/3 4, Phase 2 8, Phase 1/2 5, Phase 1 11) 2023: 345 trials (Observational 91, Not applicable 213, Phase 4 5, Phase 3 9, Phase 2 14, Phase 1/2 1, Phase 1 12) 2024: 399 trials (Observational 104, Not applicable 242, Phase 4 6, Phase 3 9, Phase 2/3 3, Phase 2 14, Phase 1/2 3, Phase 1 18) 2025: 378 trials (Observational 95, Not applicable 225, Phase 4 7, Phase 3 8, Phase 2/3 4, Phase 2 13, Phase 1/2 8, Phase 1 18)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 369
2025 378
2024 399
2023 345
2022 330
2021 407
2020 293
2019 335
2018 312
2017 292

Showing 10 of 35 earlier years.

Start your 14-day trial Email me all 35 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 400 trials starting in 2026 and about 390 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 622 trials still running at the 2026-10-09 snapshot; registered median of 27 months across 3,067 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Trauma, Nervous System trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 246
Phase 1/2 122
Phase 2 321
Phase 2/3 73
Phase 3 162
Phase 4 164
Not applicable 2,968
Observational 1,434
Expanded access 6

How many Trauma, Nervous System trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 311
Recruiting 789
Enrolling by invitation 83
Active, not recruiting 176
Available 1

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Trauma, Nervous System trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
VA Office of Research and Development 160
US Department of Veterans Affairs 52
Swiss Paraplegic Research, Nottwil 45
James J. Peters Veterans Affairs Medical Center 38

Which drugs are being tested for Trauma, Nervous System? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
DEXMEDETOMIDINE 13
METHYLPREDNISOLONE 12

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Hyperbaric Oxygen 22
type A botulinum toxin 20
Exercise 18
Control (placebo) group 16
Aerobic exercise 16

Showing 5 of 13 interventions.

Start your 14-day trial Email me all 13 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Trauma, Nervous System trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 476 30
Increased intracranial hemorrhage on serial head CT 239 1
Hospitalization 147 6
CNS 125 1
Shock 121 3

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Trauma, Nervous System? (50)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Validity of the Wechsler Abbreviated Scale of Intelligence, Second Edition (WASI-II) as an Indicator of Neurological Disease/Injury: A Pilot Study. Brain injury 2021 Yes
Association of Cerebrospinal Fluid Biomarkers of Central Nervous System Injury With Neurocognitive and Brain Imaging Outcomes in Children Receiving Chemotherapy for Acute Lymphoblastic Leukemia. JAMA oncology 2018 Yes
Predictive value of a diagnostic block in focal nerve injury with neuropathic pain when surgery is considered. PloS one 2018 Yes
Powered Exoskeletons for Walking Assistance in Persons with Central Nervous System Injuries: A Narrative Review. PM & R : the journal of injury, function, and rehabilitation 2017 Yes
Neural injury markers in intrauterine growth restriction and their relation to perinatal outcomes. Pediatric research 2017 Yes

Showing 5 of 50 publications.

Start your 14-day trial Email me all 50 publications as a PDF

Sub-conditions in MeSH (4)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages